Publication:
Novel agents in antiplatelet therapy

Simple item page
dc.contributor.authorsAğırbaşlı, Mehmet; Güvenç, Hacer; Cinçin, Altuğ
dc.date.accessioned2022-03-25T19:39:13Z
dc.date.accessioned2026-01-11T10:57:15Z
dc.date.available2022-03-25T19:39:13Z
dc.date.issued2010-07
dc.description.abstractAntiplatelet therapy is the cornerstone of management of acute coronary syndromes. Currently used antiplatelet drugs present several limitations that provoke new searches. These limitations include resistance, delay in the onset of action, risk for bleeding, variations in the individual response, and interaction with other medications (i.e. proton pump inhibitors, calcium channel blockers). New concepts and medications have emerged for the effective inhibition of platelets. Prasugrel, AZD6140 (ticagrelor), cangrelor, and SCH 530348 (thrombin receptor antagonist) are among some of the novel agents that survived randomized trials. In this review, we aimed to summarize novel concepts and agents in antiplatelet therapy.
dc.identifier.issn1016-5169
dc.identifier.pubmedPMID: 21200111
dc.identifier.urihttps://hdl.handle.net/11424/254776
dc.language.isotur
dc.relation.ispartofTurk Kardiyoloji Dernegi Arsivi: Turk Kardiyoloji Derneginin Yayin Organidir
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHumans
dc.subjectAspirin
dc.subjectPlatelet Aggregation Inhibitors
dc.subjectAdenosine
dc.subjectThiophenes
dc.subjectAcute Coronary Syndrome
dc.subjectPrasugrel Hydrochloride
dc.subjectPurinergic P2Y Receptor Antagonists
dc.subjectPiperazines
dc.subjectLactones
dc.subjectAdenosine Monophosphate
dc.subjectClopidogrel
dc.subjectPyridines
dc.subjectReceptors, Thrombin
dc.subjectTicagrelor
dc.subjectTiclopidine
dc.titleNovel agents in antiplatelet therapy
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage378
oaire.citation.startPage369
oaire.citation.titleTurk Kardiyoloji Dernegi Arsivi: Turk Kardiyoloji Derneginin Yayin Organidir
oaire.citation.volume5

Files

Collections

Araştırma Çıktıları